17 completed. 17 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 17 |
| Phase 2 | 10 | Completed 10 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis AVID200 - Scleroderma, Diffuse | Phase 1 | Completed | Bristol-Myers Squibb | 9 | 2019-01-01 | 2024-11-19 |
| Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | University of Michigan | 15 | 2017-09-25 | 2020-05-08 |
| Brentuximab Vedotin for Systemic Sclerosis Brentuximab Vedotin, Placebo - Diffuse Cutaneous Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 17 | 2017-09-20 | 2026-05-05 |
| Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma dabigatran etexilate - Scleroderma, Interstitial Lung Disease | Phase 1 | Completed | Medical University of South Carolina | 15 | 2016-02-01 | 2018-07-13 |
| Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo - Systemic Scleroderma | Phase 1 / Phase 2 | Completed | Prism Pharma Co., Ltd. | 17 | 2015-06-01 | 2017-08-17 |
| IL1-TRAP, Rilonacept, in Systemic Sclerosis Rilonacept, Placebo - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Completed | Boston University | 24 | 2011-12-01 | 2018-05-01 |
| Fresolimumab In Systemic Sclerosis Fresolimumab - Diffuse Systemic Sclerosis | Phase 1 | Completed | Boston University | 18 | 2011-01-01 | 2014-07-16 |
| A Study of the Safety and Tolerability of MEDI-551 in Scleroderma MEDI-551, Placebo - Scleroderma | Phase 1 | Completed | MedImmune LLC | 50 | 2010-03-01 | 2014-11-13 |
| A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma MEDI-546 - Scleroderma | Phase 1 | Completed | MedImmune LLC | 34 | 2009-09-01 | 2012-05-08 |
| Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis dasatinib - Scleroderma | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 47 | 2009-01-01 | 2012-02-29 |
| Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis treprostinil diethanolamine - Systemic Sclerosis | Phase 1 | Completed | United Therapeutics | 28 | 2008-12-01 | 2012-10-23 |
| A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Abatacept, Placebo - Scleroderma, Diffuse, Scleroderma, Systemic | Phase 1 / Phase 2 | Completed | Stanford University | 10 | 2008-11-01 | 2017-10-31 |
| Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis fludarabine phosphate, Mycophenolic Acid, tacrolimus - Systemic Scleroderma, Severe Systemic Sclerosis | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 3 | 2006-09-01 | 2018-06-04 |
| Mycophenolate Mofetil in Systemic Sclerosis Mycophenolate Mofetil - Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Completed | Boston University | 30 | 2006-03-01 | 2011-03-31 |
| Rapamycin vs Methotrexate in Diffuse SSc rapamycin, methotrexate - Systemic Sclerosis | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 17 | 2002-08-01 | 2016-04-11 |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
| Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | Genzyme, a Sanofi Company | 2015-03-05 |
Scleroderma, Systemic (9) · Acne Keloid (1) · Cicatrix (1) · Granuloma Annulare (1) · Keloid (1) · Lung Diseases, Interstitial (1) · Scleroderma, Localized (1)
Connective Tissue Diseases (17) · Skin Diseases (17) · Skin and Connective Tissue Diseases (17) · Scleroderma, Systemic (8) · Acneiform Eruptions (1) · Collagen Diseases (1) · Fibrosis (1) · Folliculitis (1) · Granuloma (1) · Hair Diseases (1) · Lung Diseases (1) · Necrobiotic Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1)
Mycophenolic Acid (2) · Abatacept (1) · Biopsy (1) · Bone Marrow Transplantation (1) · Brentuximab Vedotin (1) · Dabigatran (1) · Dasatinib (1) · Flow Cytometry (1) · Methotrexate (1) · Sirolimus (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · Transplantation (1) · Whole-Body Irradiation (1) · anifrolumab (1)
Boston University (3) · Bristol-Myers Squibb (2) · MedImmune LLC (2) · University of Michigan (2) · Fred Hutchinson Cancer Center (1) · Genzyme, a Sanofi Company (1) · Medical University of South Carolina (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Prism Pharma Co., Ltd. (1) · Stanford University (1) · United Therapeutics (1) · University of California, Los Angeles (1)
United States (17) · Canada (1) · United Kingdom (1)
Robert Lafyatis, MD (4) · David Fox, MD (1) · Dinesh Khanna, MD (1) · Dinesh Khanna, MD, MSc (1) · Eliza Farmer Chakravarty (1) · George Georges (1) · John J Voorhees, MD (1) · Kristan Rollins, PharmD (1) · Philip J Clements, MD, MPH (1) · Richard M Silver, MD (1) · Robert W Simms, MD (1) · Stephen Yoo, M.D. (1)
PMID 19950289, PMID 23597147, PMID 24559157, PMID 26071192, PMID 26098215, PMID 27267753, PMID 29121645, PMID 30277862, PMID 35943798, PMID 40013233
R01AI041721 (1), R21AR065089 (1), UM1AI109565 (1)